Due to an insufficient number of patients included in our study, whether TMB could predict the efficacy of combination therapy (anti-PD-(L)1 plus anti-CTLA-4) in melanoma patients required more studies to further confirm. The gene discussed is CTLA4; the disease is melanoma.